Stoke’s Persistence Pays Off With Dravet Syndrome Therapy
Results showing a 74% reduction in seizures set up Stoke for a pivotal study and could make STK-001 the first disease-modifying agent for the condition.
Results showing a 74% reduction in seizures set up Stoke for a pivotal study and could make STK-001 the first disease-modifying agent for the condition.